Mont-Saint-Guibert, Belgium – Celyad SA (formerly known as Cardio3 BioSciences, Euronext Brussels and Paris: CYAD), announced today the closing of its global offering of 1,460,000 ordinary shares, consisting of an underwritten public offering of 1,168,000 American Depositary Shares (“ADSs”), at a price of $68.56 per ADS, before underwriting discounts, and a concurrent European private placement of 292,000 ordinary shares at a price of €60.25 per share, before underwriting discounts, for gross proceeds of approximately €88.0 million ($100.1 million). All of the ordinary shares and the ADSs were offered by Celyad.
Each of the ADSs offered represents the right to receive one ordinary share.
Celyad’s ordinary shares are listed on Euronext Brussels and Euronext Paris under the symbol “CYAD.” The ADSs are listed on the NASDAQ Global Market under the symbol “CYAD.” UBS Investment Bank and Piper Jaffray & Co. acted as joint book-running managers, and Petercam SA, Bryan, Garnier & Co., LifeSci Capital LLC and Lake Street Capital Markets, LLC acted as co-managers for the global offering.
A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission on June 19, 2015.
Copies of the final prospectus for this global offering may be obtained from UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019, or by telephone at (888) 827-7275; or Piper Jaffray & Co. Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email at prospectus@pjc.com.
This press release does not constitute an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
